Cargando…
Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice
Antisense-mediated exon skipping is a promising approach for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening genetic disease due to dystrophin deficiency. Such an approach can restore the disrupted reading frame of dystrophin pre-mRNA, generating a truncated form of the p...
Autores principales: | Lu-Nguyen, Ngoc, Malerba, Alberto, Popplewell, Linda, Schnell, Fred, Hanson, Gunnar, Dickson, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363451/ https://www.ncbi.nlm.nih.gov/pubmed/28325281 http://dx.doi.org/10.1016/j.omtn.2016.11.009 |
Ejemplares similares
-
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers
Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the
Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012) -
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2022) -
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021) -
Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2019) -
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)